FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886776749> ?p ?o ?g. }

• W2886776749 abstract "Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight registrational phase 2 and 3 clinical studies. High rates of sustained virologic response at 12 weeks postdosing (SVR12) were achieved with a <1% virologic failure (VF) rate. The prevalence of baseline polymorphisms (BPs) in NS3 at amino acid position 155 or 168 was low (<3%) in patients infected with GT1, GT2, GT3, GT4, and GT6, while 41.9% of the GT5-infected patients had NS3-D168E; BPs were not detected at position 156 in NS3. The prevalence of NS5A-BPs was high across genotypes, driven by common polymorphisms at amino acid position 30 or 31 in GT2, 58 in GT4, and 28 in GT6. The prevalence of NS5A T/Y93 polymorphisms was 5.5% in GT1, 4.9% in GT3, and 12.5% in GT6. Consistent with the activity of glecaprevir and pibrentasvir against most amino acid polymorphisms in vitro, BPs in NS3 and/or NS5A did not have an impact on treatment outcome for patients infected with GT1 to GT6, with the exception of treatment-experienced GT3-infected patients treated for 12 weeks, for whom a 16-week regimen of glecaprevir/pibrentasvir was required to achieve SVR12 rates of ≥95%. Among the 22 patients experiencing VF, treatment-emergent substitutions were detected in NS3 in 50% of patients and in NS5A in 82% of patients, frequently as a combination of substitutions that conferred resistance to glecaprevir and/or pibrentasvir. The glecaprevir/pibrentasvir regimen, when the recommended durations are used, allows for a pan-genotypic treatment option without the need for baseline resistance testing." @default.
• W2886776749 created "2018-08-22" @default.
• W2886776749 creator A5017869801 @default.
• W2886776749 creator A5029752262 @default.
• W2886776749 creator A5031450708 @default.
• W2886776749 creator A5035070077 @default.
• W2886776749 creator A5035416018 @default.
• W2886776749 creator A5054725734 @default.
• W2886776749 creator A5058318375 @default.
• W2886776749 creator A5063867964 @default.
• W2886776749 creator A5078071322 @default.
• W2886776749 creator A5078780321 @default.
• W2886776749 creator A5081266398 @default.
• W2886776749 creator A5085966620 @default.
• W2886776749 creator A5086039311 @default.
• W2886776749 date "2018-10-01" @default.
• W2886776749 modified "2023-10-17" @default.
• W2886776749 title "Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials" @default.
• W2886776749 cites W118013854 @default.
• W2886776749 cites W1814244002 @default.
• W2886776749 cites W1941458012 @default.
• W2886776749 cites W1966188054 @default.
• W2886776749 cites W1991752162 @default.
• W2886776749 cites W2003780225 @default.
• W2886776749 cites W2060895146 @default.
• W2886776749 cites W2086887894 @default.
• W2886776749 cites W2096347191 @default.
• W2886776749 cites W2097706568 @default.
• W2886776749 cites W2104462601 @default.
• W2886776749 cites W2106378149 @default.
• W2886776749 cites W2111996375 @default.
• W2886776749 cites W2122987848 @default.
• W2886776749 cites W2133036275 @default.
• W2886776749 cites W2166959492 @default.
• W2886776749 cites W2185218296 @default.
• W2886776749 cites W2292090508 @default.
• W2886776749 cites W2487282667 @default.
• W2886776749 cites W2531793945 @default.
• W2886776749 cites W2577564210 @default.
• W2886776749 cites W2588942442 @default.
• W2886776749 cites W2605124318 @default.
• W2886776749 cites W2605698336 @default.
• W2886776749 cites W2614089632 @default.
• W2886776749 cites W2746084941 @default.
• W2886776749 cites W2748550554 @default.
• W2886776749 cites W2756644889 @default.
• W2886776749 cites W2761085897 @default.
• W2886776749 cites W2765116944 @default.
• W2886776749 cites W2768722273 @default.
• W2886776749 cites W2769010101 @default.
• W2886776749 cites W2772996414 @default.
• W2886776749 cites W2774567315 @default.
• W2886776749 cites W2784719900 @default.
• W2886776749 cites W2788216918 @default.
• W2886776749 cites W2791036494 @default.
• W2886776749 cites W2792190643 @default.
• W2886776749 cites W2794248499 @default.
• W2886776749 cites W2801721157 @default.
• W2886776749 cites W2802849236 @default.
• W2886776749 cites W2886776749 @default.
• W2886776749 cites W2899084700 @default.
• W2886776749 cites W4254843569 @default.
• W2886776749 doi "https://doi.org/10.1128/aac.01249-18" @default.
• W2886776749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6153825" @default.
• W2886776749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30061289" @default.
• W2886776749 hasPublicationYear "2018" @default.
• W2886776749 type Work @default.
• W2886776749 sameAs 2886776749 @default.
• W2886776749 citedByCount "51" @default.
• W2886776749 countsByYear W28867767492018 @default.
• W2886776749 countsByYear W28867767492019 @default.
• W2886776749 countsByYear W28867767492020 @default.
• W2886776749 countsByYear W28867767492021 @default.
• W2886776749 countsByYear W28867767492022 @default.
• W2886776749 countsByYear W28867767492023 @default.
• W2886776749 crossrefType "journal-article" @default.
• W2886776749 hasAuthorship W2886776749A5017869801 @default.
• W2886776749 hasAuthorship W2886776749A5029752262 @default.
• W2886776749 hasAuthorship W2886776749A5031450708 @default.
• W2886776749 hasAuthorship W2886776749A5035070077 @default.
• W2886776749 hasAuthorship W2886776749A5035416018 @default.
• W2886776749 hasAuthorship W2886776749A5054725734 @default.
• W2886776749 hasAuthorship W2886776749A5058318375 @default.
• W2886776749 hasAuthorship W2886776749A5063867964 @default.
• W2886776749 hasAuthorship W2886776749A5078071322 @default.
• W2886776749 hasAuthorship W2886776749A5078780321 @default.
• W2886776749 hasAuthorship W2886776749A5081266398 @default.
• W2886776749 hasAuthorship W2886776749A5085966620 @default.
• W2886776749 hasAuthorship W2886776749A5086039311 @default.
• W2886776749 hasBestOaLocation W28867767491 @default.
• W2886776749 hasConcept C104317684 @default.
• W2886776749 hasConcept C126322002 @default.
• W2886776749 hasConcept C132379496 @default.
• W2886776749 hasConcept C135763542 @default.
• W2886776749 hasConcept C159047783 @default.
• W2886776749 hasConcept C2522874641 @default.
• W2886776749 hasConcept C2776408679 @default.
• W2886776749 hasConcept C2776455275 @default.
• W2886776749 hasConcept C2777103181 @default.
• W2886776749 hasConcept C2778390639 @default.

• next